Published in Proc Natl Acad Sci U S A on June 06, 1995
Structural and functional insights into RAGE activation by multimeric S100B. EMBO J (2007) 1.59
TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation. J Exp Med (1997) 1.56
Induced expression of trimerized intracellular domains of the human tumor necrosis factor (TNF) p55 receptor elicits TNF effects. J Cell Biol (1997) 1.03
Structural basis for ligand-mediated mouse GITR activation. Proc Natl Acad Sci U S A (2008) 0.92
Local bioactive tumour necrosis factor (TNF) in corneal allotransplantation. Clin Exp Immunol (2000) 0.80
Development of a Novel BAFF Responsive Cell Line Suitable for Detecting Bioactive BAFF and Neutralizing Antibodies against BAFF-Pathway Inhibiting Therapeutics. Cells (2014) 0.75
Looking beneath the surface: the cell death pathway of Fas/APO-1 (CD95). Mol Med (1996) 0.75
The -383A>C TNFRI polymorphism is associated with soluble levels and clinical activity in rheumatoid arthritis. Rheumatol Int (2009) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol (1987) 43.61
Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J Biol Chem (1989) 11.06
Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci U S A (1985) 8.77
Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol (1986) 8.22
Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science (1992) 7.00
Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A (1986) 5.83
Stimulation of neutrophils by tumor necrosis factor. J Immunol (1986) 5.72
Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell (1993) 5.37
Expression cloning of the murine erythropoietin receptor. Cell (1989) 4.59
Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species. J Immunol (1987) 3.06
Induction of apoptosis by the low-affinity NGF receptor. Science (1993) 3.04
Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am J Pathol (1986) 2.95
Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J Biol Chem (1995) 2.78
Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity. Nature (1990) 2.33
Homodimerization and constitutive activation of the erythropoietin receptor. Proc Natl Acad Sci U S A (1992) 2.29
Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc Natl Acad Sci U S A (1994) 2.18
Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor. Cell (1993) 2.17
Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem (1990) 2.12
Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol (1993) 1.89
The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell (1992) 1.80
Cachexia and graft-vs.-host-disease-type skin changes in keratin promoter-driven TNF alpha transgenic mice. Genes Dev (1992) 1.68
Activation and inhibition of erythropoietin receptor function: role of receptor dimerization. Mol Cell Biol (1994) 1.47
Wasting, ischemia, and lymphoid abnormalities in mice expressing T cell-targeted human tumor necrosis factor transgenes. J Immunol (1993) 1.27
Anaemia and resistance to malaria in transgenic mice expressing human tumour necrosis factor. Immunology (1994) 1.19
Aggregation of the intracellular domain of the type 1 tumor necrosis factor receptor defined by the two-hybrid system. J Biol Chem (1994) 1.19
Ligand binding properties of the human erythropoietin receptor extracellular domain expressed in Escherichia coli. J Biol Chem (1992) 0.82
Crystallization and preliminary crystallographic analysis of a TNF-beta-55 kDa TNF receptor complex. J Mol Biol (1993) 0.81
The erythropoietin receptor: dimerization, activation, and tumorigenesis. Cold Spring Harb Symp Quant Biol (1992) 0.79
Prevention of runting and cachexia by a chimeric TNF receptor-Fc protein. Clin Immunol Immunopathol (1993) 0.77
Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science (1998) 37.15
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science (1985) 19.41
Shock and tissue injury induced by recombinant human cachectin. Science (1986) 16.24
Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci U S A (1986) 15.20
Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature (1986) 11.09
Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature (2003) 10.97
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med (1986) 10.91
Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science (1986) 9.19
Cachectin: more than a tumor necrosis factor. N Engl J Med (1987) 8.74
Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med (1985) 8.18
Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med (1985) 8.16
Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature (1985) 7.22
Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med (1988) 5.16
A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science (1985) 4.98
The tumor necrosis factor ligand and receptor families. N Engl J Med (1996) 4.49
Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level. J Exp Med (1990) 4.21
Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet (1987) 4.18
Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med (1988) 4.02
The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today (1988) 3.40
Physical contact between lipopolysaccharide and toll-like receptor 4 revealed by genetic complementation. Proc Natl Acad Sci U S A (2000) 3.03
Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med (1990) 2.79
The evolution and genetics of innate immunity. Nat Rev Genet (2001) 2.60
Genetic and physical mapping of the Lps locus: identification of the toll-4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis (1998) 2.46
Evolution of the genome and the genetic code: selection at the dinucleotide level by methylation and polyribonucleotide cleavage. Proc Natl Acad Sci U S A (1989) 2.42
Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur Cytokine Netw (2000) 2.40
A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med (1991) 2.35
Effect of gamma interferon on cachectin expression by mononuclear phagocytes. Reversal of the lpsd (endotoxin resistance) phenotype. J Exp Med (1986) 2.28
Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett (1985) 2.23
Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc Natl Acad Sci U S A (1994) 2.18
Lipoproteins of Borrelia burgdorferi and Treponema pallidum activate cachectin/tumor necrosis factor synthesis. Analysis using a CAT reporter construct. J Immunol (1991) 2.09
Diphosphoryl lipid A from Rhodopseudomonas sphaeroides ATCC 17023 blocks induction of cachectin in macrophages by lipopolysaccharide. Infect Immun (1989) 1.92
Interactive effects of the tumor necrosis factor promoter and 3'-untranslated regions. J Immunol (1991) 1.89
Constitutive synthesis of tumor necrosis factor in the thymus. Proc Natl Acad Sci U S A (1992) 1.89
PU.1 and interferon consensus sequence-binding protein regulate the myeloid expression of the human Toll-like receptor 4 gene. J Biol Chem (2000) 1.87
Alternative cleavage of the cachectin/tumor necrosis factor propeptide results in a larger, inactive form of secreted protein. J Biol Chem (1989) 1.76
Modulation of inflammation and cachectin activity in relation to treatment of experimental Hemophilus influenzae type b meningitis. J Infect Dis (1989) 1.66
Massively parallel sequencing of the mouse exome to accurately identify rare, induced mutations: an immediate source for thousands of new mouse models. Open Biol (2012) 1.65
Immunology: Toll-like receptors and antibody responses. Nature (2006) 1.64
Adenoviral vectors given intravenously to immunocompromised mice yield stable transduction of the colonic epithelium. Gastroenterology (1997) 1.64
Lipopolysaccharide signals activation of tumor necrosis factor biosynthesis through the ras/raf-1/MEK/MAPK pathway. Mol Med (1994) 1.57
Correlation of interleukin-1 beta and cachectin concentrations in cerebrospinal fluid and outcome from bacterial meningitis. J Pediatr (1989) 1.56
Excess of rare amino acid polymorphisms in the Toll-like receptor 4 in humans. Genetics (2001) 1.49
Analysis of Tlr4-mediated LPS signal transduction in macrophages by mutational modification of the receptor. Blood Cells Mol Dis (2000) 1.49
Cachectin/tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential. J Exp Med (1986) 1.49
TLR7: A new sensor of viral infection. Proc Natl Acad Sci U S A (2004) 1.49
Tumor necrosis factor in mediating experimental Haemophilus influenzae type B meningitis. J Clin Invest (1989) 1.48
Phylogenetic variation and polymorphism at the toll-like receptor 4 locus (TLR4). Genome Biol (2000) 1.35
The essential role of the UA-rich sequence in endotoxin-induced cachectin/TNF synthesis. Eur Cytokine Netw (1991) 1.34
Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease. Gastroenterology (1999) 1.33
Constitutive activity of the tumor necrosis factor promoter is canceled by the 3' untranslated region in nonmacrophage cell lines; a trans-dominant factor overcomes this suppressive effect. Proc Natl Acad Sci U S A (1992) 1.31
Cachectin/tumor necrosis factor-alpha formation in human decidua. Potential role of cytokines in infection-induced preterm labor. J Clin Invest (1989) 1.27
The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest (1992) 1.22
Porcine tumor necrosis factor alpha: cloning with the polymerase chain reaction and determination of the nucleotide sequence. Gene (1989) 1.18
A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome. J Clin Invest (1993) 1.17
Cachectin/tumor necrosis factor: an endogenous mediator of shock and inflammation. Immunol Res (1986) 1.14
The HLA-dependent expression of testis- organizing H-Y antigen by human male cells. Cell (1978) 1.12
Extinction of the tumor necrosis factor locus, and of genes encoding the lipopolysaccharide signaling pathway. J Exp Med (1993) 1.10
Complex regulation of tumor necrosis factor mRNA turnover in lipopolysaccharide-activated macrophages. Biochim Biophys Acta (1991) 1.09
Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense. J Infect Dis (1995) 1.05
Limits of a deletion spanning Tlr4 in C57BL/10ScCr mice. J Endotoxin Res (2000) 1.04
Tumor necrosis factor alpha and interleukin 1 beta in synovial fluid of infants and children with suppurative arthritis. Am J Dis Child (1990) 1.04
Unraveling innate immunity using large scale N-ethyl-N-nitrosourea mutagenesis. Tissue Antigens (2005) 1.04
Protein-energy malnutrition halts hemopoietic progenitor cells in the G0/G1 cell cycle stage, thereby altering cell production rates. Braz J Med Biol Res (2009) 0.97
Dendritic cells produce macrophage inflammatory protein-1 gamma, a new member of the CC chemokine family. J Immunol (1996) 0.97
How do tumor necrosis factor receptors work? J Inflamm (1995) 0.95
Translational control mediated by UA-rich sequences. Enzyme (1990) 0.95
Electrophoretic polymorphism of glutathione peroxidase. Ann Hum Genet (1974) 0.94
Tumor necrosis factor alpha stimulates leukotriene production in vivo. Eur J Immunol (1988) 0.93
Expression of a TNF inhibitor in transgenic mice. J Immunol (1993) 0.93
TLR signaling pathways: opportunities for activation and blockade in pursuit of therapy. Curr Pharm Des (2006) 0.93
The endogenous mediator of endotoxic shock. Clin Res (1987) 0.91
Cachectin alters anterior pituitary hormone release by a direct action in vitro. Proc Natl Acad Sci U S A (1989) 0.91
MIP-1 gamma: molecular cloning, expression, and biological activities of a novel CC chemokine that is constitutively secreted in vivo. J Inflamm (1995) 0.91
Detection of interleukin 1 beta but not tumor necrosis factor-alpha in cerebrospinal fluid of children with aseptic meningitis. Am J Dis Child (1990) 0.89
Analysis of tumor necrosis factor promoter responses to ultraviolet light. J Clin Invest (1994) 0.88
Crystallization of trimeric recombinant human tumor necrosis factor (cachectin). J Biol Chem (1988) 0.87
Cachectin: a pluripotent hormone released during the host response to invasion. Recent Prog Horm Res (1987) 0.85
Multiple splice forms of ribonuclease-inhibitor mRNA differ in the 5'-untranslated region. Gene (1989) 0.85
Effect of amrinone on tumor necrosis factor production in endotoxic shock. Circ Shock (1992) 0.84
The biosynthesis of tumor necrosis factor during pregnancy: studies with a CAT reporter transgene and TNF inhibitors. Eur Cytokine Netw (1993) 0.83
Comparative expression of TNF-alpha alleles from normal and autoimmune-prone MHC haplotypes. J Inflamm (1995) 0.81
Expression of the tumor necrosis factor gene by dermal fibroblasts in response to ultraviolet irradiation or lipopolysaccharide. J Invest Dermatol (1995) 0.80
Tumor necrosis factor and the Jarisch-Herxheimer reaction. N Engl J Med (1996) 0.79
Endotoxin-mimetic effect of antibodies against Toll-like receptor 4. J Endotoxin Res (2000) 0.79
Tumor necrosis factor-alpha and interleukin-1 beta production by human fetal Kupffer cells. Am J Obstet Gynecol (1991) 0.79
Cachexia: a fundamental mechanism. Nutr Rev (1988) 0.77
Heterozygous mis-sense mutations in Prkcb as a critical determinant of anti-polysaccharide antibody formation. Genes Immun (2013) 0.77
Expression of an adenovirally encoded lymphotoxin-beta inhibitor prevents clearance of Listeria monocytogenes in mice. J Inflamm (1995) 0.77
Cachectin: the dark side of tumor necrosis factor. Cold Spring Harb Symp Quant Biol (1986) 0.76
Receptor-mediated label-transfer assay (RELAY): a novel method for the detection of plasma tumor necrosis factor at attomolar concentrations. J Immunol Methods (1994) 0.76
Toll we meet again.... Nat Immunol (2001) 0.76
Genetic polymorphism in the human TNF region: correlation or causation? J Inflamm (1997) 0.75
University of California/Davis Interdepartmental Conference on gram-negative septicemia. Rev Infect Dis (1991) 0.75
Lymphoid hyperplasia, CD45RBhigh to CD45RBlow T-cell imbalance, and suppression of Type I diabetes mellitus result from TNF blockade in NOD-->NOD-scid adoptive T cell transfer. Diabetologia (1998) 0.75
Restoration of the lipopolysaccharide-responsive phenotype in C3H/HeJ peritoneal macrophage-P388D1 cell hybrids. J Leukoc Biol (1988) 0.75
Glutathione peroxidase activity of inorganic selenium and seleno-DL-cysteine. Experientia (1975) 0.75
Mapping of the human ribonuclease inhibitor gene (RNH) to chromosome 11p15 by in situ hybridization. Genomics (1990) 0.75